Dupilumab for refractory chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis
Dupilumab is an effective treatment option for severe and refractory ENT manifestations in EGPA, as it improves symptoms, reduces inflammation, and leads to better a quality of life. However, careful patient selection and monitoring are necessary to minimize adverse events and optimize outcomes.
Authors
- Roberto Padoan (ORCID: https://orcid.org/0000-0002-2356-375X)
- Sonny Zampollo
- Tommaso Saccardo (ORCID: https://orcid.org/0000-0002-8349-9569)
- Piero Nicolai (ORCID: https://orcid.org/0000-0003-0443-3519)
- Giancarlo Ottaviano (ORCID: https://orcid.org/0000-0003-2433-4761)
- Andrea Doria (ORCID: https://orcid.org/0000-0003-0548-4983)
- Luca Iorio (ORCID: https://orcid.org/0009-0000-2388-7001)
- F. Davanzo (ORCID: https://orcid.org/0009-0004-9429-419X)
- Giuseppe Roccuzzo (ORCID: https://orcid.org/0000-0001-6731-8054)
Institutions
- University of Padua (IT)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1093/rheumatology/keae554
- Citations
- 6
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 3.48